ALIVUS

- Promoter Nirma Limited sold 36,80,000 equity shares (2.99% stake) of Alivus Life Sciences Limited through open market transaction on November 6, 2026. - Promoter shareholding decreased from 74.73% (9,18,96,285 shares) to 71.74% (8,82,16,285 shares).

Current scenario: Q2 FY27 revenue from operations stood at INR682 crores, up 16% YoY, driven by new product launches and healthy demand across existing portfolios. Changes in trends: CDMO business delivered robust performance with revenue climbing to INR50 crores, up 80% YoY; Non-GPL business grew 20.8% YoY and now contributes 79% of overall revenues. Management Guidance & Outlook: Reiterated FY27 revenue growth guidance of 10% to 12% and EBITDA margins in the 35% to 36% range; Solapur facility Phase 1 expected to become operational in Q3 of FY27. Capex: Q2 capex was INR105 crores and H1 capex was INR190 crores; company remains net debt-free with free cash flow of INR270 crores. Growth Drivers: Expansion of high potent API portfolio, new product launches, onboarding of complex products, and scaling up the CDMO business.

Concall Schedule Concall Date: November 6, 2026 and November 12, 2026 Concall Time: Not Specified

Concall Schedule Concall Date: November 4 and November 6, 2026 Concall Time: Not specified (In-person meetings)

- Alivus Life Sciences Limited has informed the stock exchanges about the audio recording of the Q2 FY2027 Earnings Call held on October 30, 2026. - The audio recording has been made available on the company website.

- Alivus Life Sciences Limited has approved the allotment of 1,95,833 equity shares of face value ₹2 each on October 29, 2026, under the Employee Stock Option Scheme, 2021. - Consequent to this allotment, the paid-up equity share capital of the company has increased from 12,27,71,448 shares (₹24,55,42,896) to 12,29,67,281 shares (₹24,59,34,562).

- Alivus Life Sciences reported Q2FY27 revenue of ₹6,820 Mn, up 16.0% YoY. - EBITDA for Q2FY27 stood at ₹2,851 Mn, registering a 47.0% YoY growth with a record high margin of 41.8%. - PAT for Q2FY27 was ₹1,968 Mn, up 51.3% YoY with margins at 28.9%. - Strong free cash flow generation led to cash and cash equivalents of ₹10,116 Mn as of September 30, 2026. - Capex for Solapur and R&D facility in Taloja progressing on track.

Q2 FY27 Consolidated Revenue ₹6,820Mn vs ₹5,880Mn (▲16.0% YoY) EBITDA ₹2,851Mn vs ₹1,939Mn (▲47.0% YoY) PAT ₹1,968Mn vs ₹1,301Mn (▲51.3% YoY) EBITDA Margin 41.8% vs 33.0% (▲880bps)

- Alivus Life Sciences Limited has submitted financial results for the period ended September 30, 2026. - Detailed financial tables and performance figures were not provided in the filing content.

Concall Schedule Concall Date: Friday, October 30, 2026 Concall Time: 8:30 am – 9:30 am [IST]